May 23, 2017. By Jane Mundy.
Detroit, MI: Most jurors in Risperdal trials are likely sympathetic and at the same time shocked to discover how boys who developed female breasts have suffered. The public are likely reacting the same way after seeing a photo project online titled “Risperdal Boys”.Read [ Risperdal Victims Candid Photographs Speak Volumes ]
May 4, 2017. By Gordon Gibb.
Philadelphia, PA: A Risperdal lawsuit that was initially stopped following a health issue on the part of a jurist, restarted and then thrown out on the second try will be up for a third go if the plaintiff has his way.Read [ Risperdal Lawsuit Plaintiff Up for a Third Try ]
April 30, 2017. By Gordon Gibb.
Philadelphia, PA: A Risperdal lawsuit that had to be stopped and restarted after a juror suffered a health emergency, has been tossed by a Philadelphia judge after appearing to agree with defendant Janssen Pharmaceuticals that the plaintiff failed to provide sufficient evidence to fully support his claim of Risperdal gynecomastia, a condition characterized by the growth of male breast tissue. The judge, in issuing his order to dismiss the case, gave no further details.Read [ Yet Another Risperdal Lawsuit Tossed in Philadelphia ]
April 7, 2017. By Gordon Gibb.
Philadelphia, PA: The seventh Risperdal lawsuit in the mass tort in Philadelphia has heard opening arguments, with attorneys for the plaintiff suggesting that 8-year-old boys should not be growing male breasts. Legal counsel for the defense shot back that plaintiff Dean Hibbs, now 23, was obese to begin with and only took Risperdal for a period of seven months.Read [ Latest Risperdal Trial Restarted After Health Emergency Resulted in a Mistrial ]
March 20, 2017. By Gordon Gibb.
Philadelphia, PA: A Risperdal lawsuit that alleged the growth of male breast tissue (Risperdal gynecomastia) suffered by the plaintiff was stopped dead in its tracks before a trial reached the verdict stage after a Pennsylvania judge determined that Johnson & Johnson (J&J) and its Risperdal unit, Janssen Pharmaceuticals Inc. (Janssen) had not failed to adequately warn about gynecomastia risk as the plaintiff had asserted, thus pulling the rug out from under the lawsuit.Read [ Recent Risperdal Lawsuit Tossed, Plaintiffs Plan to Appeal ]
March 7, 2017. By Deb Hipp.
New Brunswick, NJ:There are now 18,500 Risperdal lawsuits pending against Johnson & Johnson (J & J) and its subsidiary Janssen Pharmaceuticals in the US and Canada, according to Johnson & Johnson's most recent annual report.Read [ Number of Pending Risperdal Lawsuits Grows to 18,500 Cases ]
February 21, 2017. By Gordon Gibb.
Philadelphia, PA: With Risperdal side effects lawsuits continuing to grow at a compelling rate within a mass tort in the Philadelphia Court of Common Pleas, the file is poised to move forward with a meeting planned for March 9 with regard to the centralized litigation (In Re: Risperdal Litigation, Case No. 100300296).Read [ Risperdal Case Load Shows No Sign of Slowing Down ]
February 10, 2017. By Deb Hipp.
Toronto, ON: A recent Canadian study found that nearly 12 percent of Ontario youth diagnosed with attention deficit hyperactivity disorder (ADHD) are prescribed antipsychotic drugs such as Risperdal (Risperidone), Zyprexa and Seroquel despite having no other mental health diagnoses.Read [ Canadian Study Finds 12 Percent of ADHD Youth Prescribed Antipsychotic Drugs Such as Risperdal ]
January 29, 2017. By Jane Mundy.
Philadelphia, PA: Litigation over the antipsychotic drug Risperdal was the second largest mass tort (just behind Reglan) in 2016 and believed to be mainly responsible for the pharmaceutical inventory in Philadelphia’s Complex Litigation Center to be “at its highest level in recent years.”Read [ Risperdal Litigation Second Largest ]
January 10, 2017. By Gordon Gibb.
Philadelphia, PA: As principles with Janssen Pharmaceuticals continued to maintain that pre-trial Risperdal settlements are one-offs and not an indication of any emerging strategy, Janssen nonetheless settled a Risperdal lawsuit Friday before what would have been the seventh Risperdal gynecomastia trial had a chance to start.Read [ Seventh Risperdal Gynecomastia Case Settled Prior to Trial ]